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Abstract 
 
Background: There is a growing interest in using cognitive behavioural therapy (CBT) with 
people who have Asperger Syndrome (AS) and comorbid mental health problems.   
Aims: To examine whether modified group CBT for clinically significant anxiety in an AS 
population is feasible and likely to be efficacious.  
Method: Using a randomised assessor-blind trial, 52 individuals with AS were randomised 
into a treatment arm or a waiting-list control arm. After 24 weeks, those in the waiting-list 
control arm received treatment, while those initially randomised to treatment were followed-
up for 24 weeks.   
Results:  The conversion rate for this trial was high (1.6:1), while attrition was 13%. After 24 
weeks, there was no significant difference between those randomised to the treatment arm 
compared to those randomised to the waiting-list control arm on the primary outcome 
measure, the Hamilton Rating Scale for Anxiety.   
Conclusions:  Trials of psychological therapies with this population are feasible.  Larger 
definitive trials are now needed.  
Declaration of Interest: None 
Trial Registration:  ISRCTN 30265294 (DOI: 10.1186/ISRCTN30265294), UKCRN 8370 
   
 
 
Keywords: Anxiety, Asperger Syndrome (AS), High Functioning Autism (HFA), autism, 
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Introduction 
Anxiety disorders and related symptomatology are commonly found amongst those 
with autistic spectrum disorders (ASDs), including Asperger syndrome (AS) (1-7).  A meta-
analysis examining the effectiveness of cognitive-behavioural therapy (CBT) for anxiety 
disorders in children with ASDs reported that treatment had an effect size of d =  1.19 for 
clinician-rated outcome measures, d =  1.21 for parent-rated outcome measures, and d =  .68 
for child self-report outcome measures (8).  The literature about the treatment of mental 
health problems for adults with ASDs using CBT remains relatively sparse; there have been 
some case studies (9, 10), and some small trials (11-14).  The aim of this trial was to collect 
data sufficient to inform the design of a definitive large scale trial.  The specific objectives 
included (a) assessing whether a CBT intervention is likely to be efficacious within a pilot, 
assessor-blind RCT with adults who have AS experiencing problems with anxiety, and (b) to 
gain participant views about taking part in therapy.  
 
Method 
Participants 
Fifty-two individuals, Mage =  35.9, SD =  14.5, 48% women, were recruited and 
enrolled within the trial from Kent, South East London and Norfolk within the United 
Kingdom. Recruitment took place within the community from AS/autism teams, AS user 
groups, such as Asperger East Anglia, the Kent Autistic Trust, Bridging the Gap, the 
Disability and Dyslexia Support Services at the University of Kent, learning disability teams, 
adult mental health teams, and through public advertisements.  Participant flow throughout 
the trial is found in Figure 1, and further demographic information can be found in Table 1.   
 
Insert Figure 1 about here 
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All participants were initially screened by research workers to determine eligibility to 
take part in the trial. The inclusion criteria were: a) participants fulfilled diagnostic criteria 
for AS, high functioning autism (HFA) or pervasive developmental disorder – not specified 
(PDD-NS); diagnosis was confirmed by inspection of previous records, or the study team 
used the Autism Diagnostic Observation Schedule to confirm the diagnosis,  b) participants 
had clinically significant difficulties with anxiety as confirmed through the use the Hamilton 
Rating Scale for Anxiety; score of >14 qualified inclusion,  c) participants were between 16-
65 years of age, d) Full Scale IQ >70 on the Wechsler Abbreviated Scale of Intelligence (15). 
The exclusion criteria were:  a) participants with post-traumatic stress disorder, or anxiety 
related to substance misuse, b) co-morbid severe psychiatric disorders that impair capacity to 
consent to take part (e.g. florid symptoms of psychosis), and c) current substance abuse such 
as alcohol or drugs.    
Insert Table 1 about here 
 
Design and Randomisation 
This study was an assessor-blind randomised trial.  Our full protocol has been 
published elsewhere (16).  Masked researchers enrolled participants and carried out the 
assessments.  Even pairs of participants were allocated to the treatment arm (group CBT + 
Treatment as Usual (TAU) for 24 weeks) or the waiting-list control arm (TAU for 24 weeks) 
using blocked randomisation with random even blocks, stratified by study site.  The 
therapists at each research site contacted participants to inform them of their group allocation.  
All data were stored independently by the Norwich Clinical Trials Unit based at the 
University of East Anglia, who also carried out randomisation.  Once randomisation had been 
completed, therapists were informed, who then informed participants.    
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After the initial 24 weeks of treatment, those within the waiting-list control group 
received 24 weeks of group CBT, while those who had already taken part in group CBT 
continued to receive TAU for a further 24 weeks. Both groups were assessed again following 
this further 24-week period.  This allowed for 50% of the participants, those who received 
treatment first, to be followed up for a six month period.  Following the completion of all 
study outcome measures, participants were interviewed and invited to give their opinions on 
the intervention and asked to make suggestions about what they would like changed.  
Participants completed the outcome measures on three occasions, a) Baseline, b) Follow-up 
1, and c) Follow-up 2.    
Ethical considerations 
A favourable ethical opinion was obtained from the Cambridgeshire 4 NHS Research 
Ethics Committee (Reference: 10/H0305/42).  Informed consent was sought from participants 
and their carers, who completed the Social/Emotional Functioning Interview – Informant 
Version.  Participants were afforded time to consider whether they wanted to participate and 
were given the opportunity to ask any questions. Information about the study was provided in 
an “easier to read” format for participants who may have had reading difficulties.  
Participants were told that they could withdraw from the trial at any stage without giving a 
reason, and this would not affect access to other treatments or services. Adverse events 
relating to the trial were monitored throughout and none were detected.   
Intervention 
The intervention used within this study comprised 24 weekly sessions, each lasting 
approximately one hour.  Participants received 3 initial sessions of 1:1 CBT, followed by 21 
group CBT sessions.   All sessions took placed within community-based settings.  The initial 
three sessions of therapy aimed to help socialise each participant into CBT and to address any 
concerns they may have about joining the group.  At least two therapists were present for 
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each group session.  In order to ensure adherence to treatment, a treatment manual (17) was 
developed with specific aims for each session, and all sessions were delivered by a registered 
clinical psychologist or a qualified cognitive-behavioural therapist.  The treatment manual 
included the following topics, (a) psychoeducation about ASDs and anxiety, (b) cognitive 
restructuring, (c) anxiety management techniques, (d) systematic desensitization, (e) exposure 
to feared social situations, and (f) social skills training.  These skills were practiced in vivo.  
In addition to the intervention, participants in both arms before and after cross-over received 
TAU.   The description of our intervention is intentionally brief within this paper as the 
complete treatment manual, which includes all of the session-by-session content can be 
downloaded from http://www.kent.ac.uk/tizard/staff/acadstaff/pete_langdon.html. 
Outcome Measures and Analysis 
Our primary outcome measure was the Hamilton Rating Scale for Anxiety.  Data were 
collected at participants’ homes, the university, or in community-based clinical settings.  
Primary outcome measure. Hamilton Rating Scale for Anxiety (18). This is a 
structured clinician rated scale incorporating 14 factors which are considered valid indicators 
of anxiety. Each factor reflects a symptom of anxiety; physical as well as mental symptoms 
are represented. The factors are scored on a 5-point scale as part of a structured interview.   
 Secondary outcome measures. Social Phobia Inventory (19).  This is a 17-item 
self-report measure of behavioural, physiological and cognitive symptoms associated with 
social phobia. Participants rate the frequency with which they experience each symptom over 
the last week, using a five-point Likert-type scale (0-4).  Liebowitz Social Anxiety Scale (20). 
This instrument is a self-report scale that assesses fear and avoidance throughout 24 listed 
situations, which are likely to elicit social anxiety.  Social and Emotional Functioning 
Interview (Informant and Subject Versions) (21). This is a semi-structured clinician rated 
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assessment of everyday social and psychiatric functioning that was designed to assess 
independence, leisure, interpersonal problems, employment, and social relationships.  Some 
items are shared with the Autistic Diagnostic Observation Schedule. This measure was 
completed with each participant, and a nominated informant.  Social Interaction Anxiety 
Scale (22, 23). A self-report 20- item measure of anxiety as experienced in social situations 
associated with social anxiety and social phobia in accordance to the DSM-IV criteria. 
Experiences are rated on a 5-point scale from 0 (not at all characteristic of me) to 4 
(extremely characteristic of me). Fear Questionnaire (24). A self-report questionnaire 
regarding the individual perception of fears and phobias; respondents are asked how likely 
they are to avoid each of the listed situations, due to anxiety/fear or any other unpleasant 
feelings.  In addition to the 15 pre-existing items the individual is asked to document and 
score any individual phobias they would wish treated. Hamilton Rating Scale for Depression 
(25). This structured clinician rated interview is considered a valid indicator of depression 
and the ratings are based on the interviewer’s objective and subjective perceptions during the 
assessment.  Eight items are scored on a 0 (not present) to 4 (severe) point scale, and nine 
items are scored from 0-2 (levels of severity).  Views about therapy.  Following the 
completion of the trial, participants were interviewed, and asked to rate nine questions on a 
five point Likert Scale about their experiences of receiving therapy.  Participants were also 
asked the five following questions, with supplementary questions used for clarification, 1) 
“What were you hoping for by taking part in this research study?”, 2) “What was best about 
the group?”, 3) “What was worst about the group?”, 4) “What advice would you give for the 
next group?”, and 5) “Were there any difficulties you feel that the group did not address?”.  
Health Economics.  Generic health related quality of life (EuroQol EQ-5D) and health 
service contact data were also collected.  These will be reported separately (manuscript in 
preparation) and includes some description of TAU.     
Running Head: The PAsSA Trial 
 
Page 8 of 28 
 
Analysis.  Data were analysed using SAS Version 9.4 by a subgroup blind statistician (LS), 
controlling for baseline scores, making use of the Intent-to-Treat principle; the analysis was 
completed using the originally assigned groups. The initial group allocation for participants 
did not change throughout the trial.  Data about participants’ views of taking part in therapy 
were subjected to both a frequency and descriptive thematic analysis.  A supplementary 
analysis was completed using participants who attended at least 50% of the treatment 
sessions at Follow-up 1 in order to examine whether outcomes were different for those who 
attended a greater number of sessions.   
Results 
 
 Considering recruitment, 83 participants were approached and 52 were enrolled; this 
is a conversion rate of 1.6 participants to 1 participant.  Seven participants were lost 
throughout the trial, representing an attrition rate of 13%.   One participant told us that they 
withdrew because they found travelling to the group too difficult.  Another three participants 
said that they no longer wanted to attend the group because it was either too difficult for 
them, or something they found unhelpful.   The other participants did not respond to our 
attempts to contact them.  
 
The two treatment arms were well matched on IQ, age, sex and the primary outcome 
measure (Table 1 & 2).  Both groups scored in the “mild to moderate” or “moderate to 
severe” ranges on the Hamilton Rating Scale for Anxiety (HAM-A).  Participants were 
predominately white British, single and without children (Table 1).   The two groups did not 
differ significantly in terms of the number of treatment sessions they attended, t (50) = < 1, p 
= .774 (Table 2).   
  
Running Head: The PAsSA Trial 
 
Page 9 of 28 
 
 Turning to consider the primary outcome measure, HAM-A mean scores significantly 
improved over Time, regardless of arm, and regardless of Baseline scores, F (2, 84) = 43.67, 
p < .001.   Controlling for Baseline scores, there was no significant difference between the 
Treatment and Wait List arms at either Follow-up 1 or 2 on the HAM-A (Table 2).    
 
Considering the secondary outcome measures, there was a significant improvement 
over Time, regardless of arm, and Baseline scores, on the Hamilton Rating Scale for 
Depression (HAM-D), F (2, 84) = 7.84, p = .008, Fear Questionnaire Total Phobia Score, F 
(2, 84) = 6.00, p = .019, Liebowitz Avoidance, F (2, 84) = 10.52, p = .003, Liebowitz 
Fear/Anxiety, F (2, 84) = 10.90, p < .002, Social Interaction Anxiety Scale, F (2, 84) = 16.75, 
p < .001, Social Phobia Inventory, F (2, 84) = 8.15, p = .007, and the Social/Emotional 
Functioning Interview – Informant, F (2, 84) = 30.87, p < .001, and Subject Versions, F (2, 
84) =  17.37, p < .001 (Table 3).  Controlling for Baseline scores, there was no significant 
difference between the Treatment and Wait List arms on any of the secondary outcomes at 
Follow-up 1 or 2 (Table 3).   
 
Just over half (53%) of the participants agreed or strongly agreed that the individual 
sessions that were initially offered helped prepare them for the group sessions.  It was also 
the case that over half (59%) of the participants agreed or strongly agreed they now knew 
how to reduce their feelings of anxiety following treatment.   However, 38% of participants 
thought there was insufficient time during sessions and 41% thought there were too few 
sessions.  Seventy-nine percent of participants agreed or strongly agreed that they found 
listening to the problems of others helpful, while near 80% agreed or strongly agreed that 
they felt supported by other group members.  Just over half (56%) agreed or strongly agreed 
that therapy reduced their anxiety, while 44% responded as either neutral, disagreed, or 
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strongly disagreed about this.  Seventy-three percent of participants agreed or strongly agreed 
that they would recommend therapy to others, and 73% agreed or strongly agreed that 
therapy was helpful (Table 4). 
 
Turning to consider the open ended questions that participants were asked at the end 
of the trial about their experience of taking part in therapy, five clear themes emerged which 
are largely framed around the questions asked.  The first was labelled, “Motivation to Take 
Part”.   Participants described taking part in the trial in order to access help for their mental 
health problems, while others had hoped that they might form new relationships with other 
people with ASDs.   Many told us that they wanted to “change their life for the better” and 
recognised that anxiety was having a detrimental effect upon their wellbeing and ability to 
manage their lives.    
 
The second theme was labelled, “Positive Experiences”.  Participants described that 
they enjoyed “interacting with the others; meant a lot because we could share and listen to 
each other”.   Some commented on the inherent value of learning that they are “not alone and 
others have the same problems”.   Several talked about how being in the group helped them 
to “open up more”.   Participants also told us that they “enjoyed learning new skills” which 
helped them to cope better with difficulties.   There was evidence from some participants that 
they derived benefit from the group; one person said, “I was pleased to come away with 
coping strategies”, while another said, “I used to go out seven times in 22 years and now I 
can go wherever”.  Another said that they found the group, “enjoyable and fulfilling”, and 
some participants talked about seeking further access to psychological therapies elsewhere 
because the trial had finished.     
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The third theme was labelled, “Negative Experiences”.   Many participants were clear 
that they wanted to have had longer sessions.  One commented, “by the time we open up and 
talked about what bothered us…the group stopped”.   Some suggested longer sessions of 90 
to 120 minutes.   Others spoke about issues around the dynamics of being in a group, with 
one participant stating, “the group could be easily hijacked”.  Participants considered that 
sometimes their problems were not addressed because other group members talked more.   
Others felt that some group members spoke about “irrelevant issues” and felt that the 
therapists should have re-focused the group more frequently.   Several spoke about needing 
more continuity and greater focus on making sure the sessions flowed more effectively, while 
there were a few participants who commented that they found taking part in a group very 
difficult and thought the whole experience was negative. However, several commented that 
they could not think of anything negative about the groups, and several said that the most 
negative aspect was “ending” and they “missed the group”.   
 
The fourth theme was labelled, “Further adaptations”.   Participants described a 
variety of changes that they would like in order to improve therapy for the future.  This 
included, “more preparatory work” for those who found groups difficult, and several 
suggested that more individual sessions might motivate some people to change.  One person 
talked about wanting to alternate between blocks of group sessions and individual sessions.   
Many participants recommended that they would like to see longer sessions in the future 
which would allow them to consider their problems in “more depth, like depression” and 
“greater work on social skills and friendships”.    While several said they really enjoyed 
homework tasks, some commented that they would like “multi-media options, like DVDs, 
pictures and audio” for homework and during the sessions.    
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The final theme to emerge was titled, “Pragmatic Issues”.  Participants told us that 
there were sometimes issues with public transport, travelling, the timings of the group, 
heating in the rooms, and difficulties with parking, all of which they did not like.   
 
Supplementary Analysis 
 In order to consider whether there may have been a relationship between the number 
of sessions attended and outcome, those who had received treatment were split into two 
subgroups at Follow-up; those who had attended <50% of the treatment sessions and those 
who had attended ≥50% of the treatment sessions.  Considering only those participants who 
had attended ≥50% of the treatment sessions, increased the magnitude of difference between 
the treatment and waiting list control arm on the primary outcome measure at Follow-up 1 
greater than that reported using our per-protocol analysis, although the difference was not 
statistically significant (Table 5). 
Discussion 
 
 The conversion rate within this trial was high, and the attrition rate was much lower 
than that reported within other clinical trials of psychological therapies for anxiety disorders 
(26), suggesting that trials in this area are feasible. Nevertheless, the results indicated that 
over time, regardless of arm, anxiety symptoms improved significantly.  There are likely to 
be several reasons for this finding; the most likely is that as this is a pilot trial, the probability 
of making a Type II error had been elevated because of the sample size.  Second, it may have 
been the case that enrolment within the trial led to “spontaneous recovery” amongst those 
randomised to the waiting-list arm.  While we did not include a placebo or attention-control 
condition within this trial, there is evidence that the placebo response has a greater effect 
within smaller trials (27).  All of the participants in our trial were told to expect treatment, 
and for one-half of them, they were told that this treatment would be delayed by six-months.  
Running Head: The PAsSA Trial 
 
Page 13 of 28 
 
Over this six-month period, by instilling a sense of hope and expectation, a placebo response 
could have occurred, resulting in a reduction in symptoms.  Interestingly, Wampold et al. 
(28) reanalysed the data used in a previous meta-analysis investigating  placebo effects within 
trials (27).  They reported no differences between the effect size associated with the treatment 
and placebo arms within trials when a disorder was, 1) likely to be affected by psychological 
factors, and 2) investigated using a robust methodology.  Third, it is important to consider 
that we did not stop any ongoing or existing treatments for those participants randomised to 
the waiting-list arm.  It may have been the case that TAU led to a significant reduction in 
symptoms for those participants randomised to the waiting-list arm.  Fourth, participants on 
average attended 13.6 treatment sessions.  It may be the case that participants did not receive 
a sufficient dose of the intervention, and combined with the sample size, significant treatment 
effects were therefore not observed.  Further, it could also be the case that treatment was not 
effective.   However, all of this must be balanced against the fact that this was a pilot trial, as 
opposed to a definitive trial, and conclusions regarding treatment effectiveness are therefore 
premature.   Our supplementary analysis suggested that there may be a relationship between 
the number of treatment sessions attended and outcome, although once again, such a 
conclusion is highly tentative considering the nature of this pilot trial.  It is possible that those 
who attended <50% of the treatment sessions had greater difficulties with anxiety and found 
the group intervention more challenging.     
 
 The interviews with participants led to a wealth of information about the intervention 
that is useful for future trials.  First and foremost, while a majority of participants reported 
that they found the intervention useful, and enjoyed attending the groups, they also told us 
that the sessions were too short.  When providing psychological interventions for people who 
have ASDs, it is important to ensure that participants have sufficient time to engage 
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meaningfully within the intervention, considering their information processing difficulties.  
Within the context of group-based interventions, therapists need to make sure that they 
manage and balance the needs of the group, and the needs of individual members, 
sufficiently. Based on our findings, we would recommend group sessions last at least 2 hours.   
Second, participants made several suggestions for adapting psychological therapies further, 
which again should be considered by both researchers and clinicians working in this area.  
Participants indicated they may benefit from more individual sessions, and the suggestion to 
alternate between blocks of both group and individual sessions improve treatment efficacy.  
Such a strategy would allow for greater focus on formulation-driven interventions for clients 
individually, while at the same time, allowing for any additional therapeutic benefits that may 
be derived from being part of a group.  This would also help to ensure that clients are 
afforded sufficient time to address their difficulties, something which may take longer for 
some people with ASDs.   Third, participants asked for more innovative homework options, 
using technology.  This may have a positive impact upon engagement.    Finally, there were 
some participants who found taking part in group-based psychological therapy difficult, 
which appeared to be associated with difficulties with social communication, coupled with 
marked anxiety problems.  It would be important to consider within any future trial whether 
group-based interventions are appropriate for all participants, and while the aforementioned 
strategy of alternating between individual and group-based session may be helpful, it may be 
the case that for some people with ASDs, group-based interventions are unlikely to be 
helpful, considering their difficulties, and such individuals should be offered individual 
sessions exclusively.   
 
 It is important to mention some of the strengths and weaknesses associated with this 
trial.  First, dealing with strengths, the design and methodology were very robust:  all of the 
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assessors were masked, and the intervention was standardised.  Randomisation and the data 
were handled independently, while the analysis was undertaken by a subgroup blind 
statistician using the Intent-to-Treat principle.    Participants were drawn from a range of 
sources and all had a confirmed diagnosis of an ASD along with comorbid problems with 
anxiety.   It was also helpful to have interviewed participants about their views of therapy, 
providing information to inform a definitive trial.  Turning to weaknesses, the current design 
ensured that all participants received treatment within the context of the research study.  Such 
a design though, as mentioned above, may have led to “spontaneous recovery” within this 
study.  A parallel design, incorporating an attention-control condition may have been more 
appropriate and should be considered for definitive trials.     
 
Finally, recently published NICE Guidelines (29) called for greater support and 
service planning for those with ASDs, and despite the high prevalence of affective disorders 
in this population, there are no known definitive trials investigating the efficacy of 
psychological interventions for this population.  The research recommendations made as part 
of the NICE Guidelines (29) suggested that trials of CBT for people with ASDs needed to 
consider the delivery method and duration of the intervention, and should test novel 
treatments in a series of pilot studies, leading to the development of definitive trials.  The 
current study has addressed some of these recommendations, and a large scale definitive trial, 
incorporating the changes to treatment as outlined, is now needed to determine whether 
treatment is effective, which we are currently planning. 
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Figure 1: Consort diagram depicting participant flow throughout the trial.  
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Excluded (n = 14)    Not meeting inclusion criteria (n = 8 )    Declined to participate (n = 4)    Exclusion criterion met (n = 1 )    Dropped out (n = 1)    Chose to receive therapy elsewhere (n = 1) 
Allocated to Waiting List (n = 25) 
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Table 1: Baseline Characteristics   
  Group 
  Treatment Arm 
(N = 26) 
Waiting List  
(N = 26) 
Combined 
(N = 52) 
Age 
Mean 
SD 
Minimum 
Maximum 
33.1 
14.6 
20 
64 
38.7 
14.3 
17 
65 
35.9 
14.6 
17 
65 
Sex Male 
Female 
12 (46%) 
14 (54%) 
15 (58%) 
11 (42%) 
27 (52%)  
25 (48%)  
IQ Mean 
SD 
Minimum 
Maximum 
106.18 
17.14 
71.00 
135.00 
104.83 
11.51 
74.00 
128.00 
105.51 
14.33 
71.00 
135.00 
Ethnicity White British 
White Other 
25 (96%) 
  1 (4%) 
26 (100%) 
  0 
51 (98%) 
  1 (2%) 
Marital 
Status 
Single 
Co-habiting 
Married 
Divorced 
19 (73%) 
  0 
  4 (15%) 
  3 (12%) 
17 (65%) 
  2 (8%) 
  5 (19%) 
  2 (8%) 
36 (69%) 
  2 (4%) 
  9 (17%) 
  5 (10%) 
Children None 
One 
Two 
Three 
> Three 
20 (77%) 
  0 
  2 (  8%) 
  4 (15%) 
  0 
20 (77%) 
  2 (8%) 
  3 (12%) 
  0 
  1 (4%) 
40 (77%) 
  2 (4%) 
  5 (10%) 
  4 (8%) 
  1 (2%) 
Education Primary or less 
Secondary 
Tertiary 
University 
degree 
  1 (4%) 
  7 (27%) 
  8 (31%) 
10 (38%) 
  0 
  9 (35%) 
  9 (35%) 
  8 (31%) 
  1 (2%) 
16 (31%) 
17 (33%) 
18 (35%) 
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Table 2: Mean Session Attendance and Primary Outcome Measure – Hamilton Rating Scale for 
Anxiety 
 Group   
 Treatment 
Arm (N=26) 
Waiting List  
(N=26) 
Mean Difference 
95% C.I. , p-value 
Adjusted Mean Differencea 
95% C.I. , p-value 
Session Attendance 
 M = (SD) M = (SD)   
 13.3 (7.17) 13.9 (7.27) -.58, [-3.4, 4.6], p = .774 - 
Hamilton Rating Scale for Anxiety 
 M = (SD) M = (SD)   
Screening 27.2 (11.23) 
N=26 
25.3 (13.92) 
N=26 
 - 
Baseline 25.7 (11.99) 
N=26 
22.8 (9.45) 
N=26 
 - 
Follow-up 1 
 
15.5 (7.91) 
N=23 
16.3 (7.54) 
N=25 
-.84 [-5.3, 3.6], p = .708 -2.46, [- 5.9, 1.0], p = .161 
Follow-up 2 13.3 (8.57) 
N=22 
13.6 (5.35) 
N=23 
-.29 [-4.6, 4.0], p = .892 -.91, [- 5.0, 3.2], p = .659 
aResulting from an ANCOVA including baseline score 
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Table 3: Secondary Outcome Measures: Means (Standard Deviations) 
  Group  
  
Treatment Waiting List 
Adjusted Mean Differencea 
95% C.I. , p-value 
Hamilton Rating Scale - Depression Baseline 20.5 (9.51) 17.5 ( 8.56)  
 Follow-up 1 17.5 (8.08) 17.2 (6.61) -1.42, [- 4.7, 1.9], p = .396 
 Follow-up 2 16.5 (9.68) 13.6 (5.39) 2.09, [- 2.4, 6.6], p = .353 
Fear Questionnaire - Total Phobia Baseline 50.9 (20.71) 42.3 (17.48)  
 Follow-up 1 43.2 (19.20) 36.1 (20.73) -.66, [-10.1, 8.8],  p = .890 
 Follow-up 2 43.7 (22.87) 33.4 (21.54) 6.18, [-6.6, 18.9],  p = .338 
Fear Questionnaire - Avoidance  Baseline   6.1 (2.40)   4.2 (3.16)    
 Follow-up 1   5.5 (2.79) 4.6  2.90) 1.68, [-0.0, 3.4], p = .052 
 Follow-up 2 5.1 (2.41)  3.5 (2.91) .13, [-1.7, 2.0], p = .890 
Fear Questionnaire - Anxiety/Depression Baseline 23.2 (10.03) 20.7 (9.60)  
 Follow-up 1 21.4 (8.58) 19.1 (9.98) .06, [-4.0, 4.1], p = .977 
 Follow-up 2 18.4 (9.75) 16.5 (9.25) 1.21, [- 4.2, 6.6], p = .657 
Fear Questionnaire - Global Rating Baseline   5.2 (2.23)   4.9 (1.97)  
 Follow-up 1   3.0 (2.70)   3.8 (2.39) -1.11, [-2.4, 0.2], p = .094 
 Follow-up 2 3.5 (2.60) 3.2 (1.92)   .02, [-1.2, 1.3], p = .980 
Liebowitz Avoidance Baseline 42.2 (14.81) 40.3 (13.94)  
 Follow-up 1 39.2 (14.31) 34.1 (15.77)   1.47, [-5.0, 8.0], p = .652 
 Follow-up 2 34.5 (17.61) 28.8 (12.42) 6.40, [-1.5, 14.3], p = .114 
Liebowitz Fear/Anxiety Baseline 43.4 (15.10) 43.4 (13.99)  
 Follow-up 1 42.2 (12.81) 36.8 (15.66) 3.09, [-2.2, 9.0], p = .299 
 Follow-up 2 39.1 (16.33) 31.6 (13.72)   7.33, [-0.8, 15.5], p = .080 
Social Interaction Anxiety Scale Baseline 43.9 (13.56) 42.3 (13.53)  
 Follow-up 1 41.5 (14.08) 39.8 (16.59) .02, [-5.0, 5.1], p = .994 
 Follow-up 2 39.8 (14.65) 35.6 (13.22) 3.01, [-3.9, 9.9], p = .390 
Social Phobia Inventory Baseline 34.3 (16.57) 31.6 (16.94)  
 Follow-up 1 33.0 (14.08) 25.4 (15.84) 4.69, [-1.7, 11.0], p = .147 
 Follow-up 2 27.2 (16.20) 24.3 (14.74) 1.99, [-5.9, 9.9], p = .616 
Social/Emotional Functioning 
Interview – Informant Version – Total 
Score 
Baseline 57.5 (17.30) 53.8 (17.58)  
Follow-up 1 52.5 (18.52) 51.2 (15.97) -3.22, [-83, 1.9], p = .210 
Follow-up 2 45.6 (16.16) 39.8 (14.78) 3.32, [-3.7, 10.3], p = .343 
Social/Emotional Functioning 
Interview – Subject Version – Total 
Score 
Baseline 48.2 (21.22) 47.1 (23.71)  
Follow-up 1 46.0 (18.94) 42.7 (14.41) 1.78, [-3.2, 6.8], p = .478 
Follow-up 2 38.1 (18.00) 31.7 (12.28) 5.96, [-2.9, 14.8], p = .183 
aResulting from an ANCOVA including baseline score 
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Table 4:  Participants Responses to the Questionnaire about Experiences of Receiving Therapy 
Question 
Strongly 
Agree Agree Neutral Disagree 
Strongly 
Disagree 
The individual therapy prepared me for the 
group therapy 
26.5% 26.5% 35% 12% - 
Since attending, I now know what I can do to 
help reduce my anxious feelings 
21% 38% 23.5% 12% 6% 
There was sufficient time in sessions for my 
problems to be addressed 
26.5% 21% 15% 38% - 
There were enough sessions for my needs  18% 35% 6% 38% 3% 
Listening to other group members talking 
about their problems was useful to me. 
41% 38% 15% 6% - 
I felt supported by the other group members 
during the sessions. 
26.5% 53% 12% 9% - 
I think the therapy has improved my anxiety  18% 38% 32% 6% 6% 
I would recommend the therapy to others  41% 32% 15% 9% 3% 
Overall, the therapy was helpful to me 29% 44% 15% 9% 3% 
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Table 5:  Supplementary analysis using participants who attended < or ≥ 50% of the total 
treatment sessions prior to Follow-up 1 and 2.   
 
 Group   
  
Treatment Arm  
 
Waiting List  
Adjusted Mean 
Differencea 
95% C.I. , p-value 
Hamilton Rating Scale for Anxiety 
 M = (SD) M = (SD)  
Follow-up 1    <50% Sessions  18.2 (6.91), n = 3 
16.3b (7.74), n = 25 -3.38 [-7.03, .27], p=.08 ≥50% Sessions  14.5 (8.21), n = 17 
Follow-up 2    <50% Sessions  
13.3b (8.57), n = 22 
13.0 (3.46), n = 3  ≥50% Sessions  13.7 (5.64), n = 20  
aResulting from an ANCOVA including baseline score; bMean calculated using subgroup sample size 
not split by session attendance. 
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APPENDIX 1:  CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported on 
page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for 
abstracts) 
2 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 3 
2b Specific objectives or hypotheses 3 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 4 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 4 
4b Settings and locations where the data were collected 6 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
5-6 
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Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were 
assessed 
6-7 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 4 (Protocol) 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 4 
8b Type of randomisation; details of any restriction (such as blocking and block size) 4 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
4 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
4 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
4 
11b If relevant, description of the similarity of interventions N/A 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 8 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 8 
Results 
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Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were 
analysed for the primary outcome 
18 (Figure 1) 
13b For each group, losses and exclusions after randomisation, together with reasons 18 (Figure 1) 
Recruitment 14a Dates defining the periods of recruitment and follow-up 5 
14b Why the trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 19 (Table 1) 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by 
original assigned groups 
18 (Figure 1) 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision 
(such as 95% confidence interval) 
21 (Table 3) 
22 (Table 4) 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/A 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-
specified from exploratory 
9-11 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 5 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 14 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 14 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 12-15 
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Other information  
Registration 23 Registration number and name of trial registry 2 
Protocol 24 Where the full trial protocol can be accessed, if available 4 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 1 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on 
all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-
pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references 
relevant to this checklist, see www.consort-statement.org. 
 
